Item 7.01. Regulation FD Disclosure.

On May 25, 2022, Aravive, Inc. (the "Company") issued a press release announcing the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually.

Safety and clinical activity of batiraxcept as monotherapy in heavily pretreated patients with no curative intent, in combination with cabozantinib (cabo) in patients who had failed first line and subsequent therapies, and in combination with cabo and nivolumab (nivo) as first line therapy were evaluated.

The abstract was released by ASCO today and contains data available as of January 17, 2023. The poster will be presented at ASCO on June 3, 2023 and will have more mature data as of April 21, 2023 and will include:

? Batiraxcept monotherapy and batiraxcept plus cabo or cabo/nivo demonstrated a

manageable safety profile, consistent with cabo and nivo prescribing

information.

? Batiraxcept plus cabo showed promising results in previously IO and

VEGF-TKI-treated ccRCC patients, with an objective response rate (ORR) of 50%

in this population (n=12), compared to 38% (n=13) in patients with no prior

VEGF-TKI.

? Batiraxcept plus cabo and nivo showed an ORR of 55% (n=11) in first-line

treatment, consistent with combination first line therapies.

? In the batiraxcept monotherapy cohort (n=10), one patient attained stable

disease, suggesting that batiraxcept achieves greatest activity in combination

therapies, supporting the intended combination approach in the planned

registrational Phase 3 trial.

? The combination of batiraxcept and cabo appears to improve median

progression-free survival (mPFS) in patients previously treated with IO and

VEGF-TKI treatments compared to those without prior VEGF-TKI exposure,

consistent with the P1b data and supporting the intended target population of

the planned Phase 3 trial.

A copy of the abstract titled "Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)" is filed as an exhibit to this Current Report on Form 8-K.

The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The press release furnished as Exhibit 99. to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

Item 8.01. Other Events.

The Company presented updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. Safety and clinical activity of batiraxcept as monotherapy in heavily pretreated patients with no curative intent, in combination with cabozantinib (cabo) in patients who had failed first line and subsequent therapies, and in combination with cabo and nivolumab (nivo) as first line therapy were evaluated.

The abstract was released by ASCO today and contains data available as of January 17, 2023. The poster will be presented at ASCO on June 3, 2023 and will have more mature data as of April 21, 2023 and will include:



  ? Batiraxcept monotherapy and batiraxcept plus cabo or cabo/nivo demonstrated a
    manageable safety profile, consistent with cabo and nivo prescribing
    information.


  ? Batiraxcept plus cabo showed promising results in previously IO and
    VEGF-TKI-treated ccRCC patients, with an objective response rate (ORR) of 50%
    in this population (n=12), compared to 38% (n=13) in patients with no prior
    VEGF-TKI.


  ? Batiraxcept plus cabo and nivo showed an ORR of 55% (n=11) in first-line
    treatment, consistent with combination first line therapies.


  ? In the batiraxcept monotherapy cohort (n=10), one patient attained stable
    disease, suggesting that batiraxcept achieves greatest activity in combination
    therapies, supporting the intended combination approach in the planned
    registrational Phase 3 trial.


  ? The combination of batiraxcept and cabo appears to improve median
    progression-free survival (mPFS) in patients previously treated with IO and
    VEGF-TKI treatments compared to those without prior VEGF-TKI exposure,
    consistent with the P1b data and supporting the intended target population of
    the planned Phase 3 trial.

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
Number      Exhibit Description
 99.1         Press Release of Aravive, Inc.
 99.2         Abstract titled "Phase 2 Study of Batiraxcept (AVB-S6-500, an AXL
            inhibitor) as Monotherapy, in combination with Cabozantinib (Cabo), and
            in combination with Cabo and Nivolumab (Nivo) in Patients with Advanced
            Clear Cell Renal Cell Carcinoma (ccRCC)"
  104       Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses